Alnylam Pharmaceuticals Inc (ALNY)
Email Confirmation
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME
Overview
News
People
Financials
Company Information
Overview
A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.
News Feeds
-
Alnylam shares fall on Europe patent dispute loss
AP
Jul 11 2008
-
Movers roundup: Tuesday Morning, Teva Pharma
AP
Jul 11 2008
Press Releases
-
Alnylam Announces Extension of RNAi Therapeutics Collaboration with Novartis Jul-16-2008, 06:34AM EDT
-
Alnylam Provides Update on "Glover" Patent Jul-10-2008, 05:00PM EDT
-
Regulus Therapeutics Selected for Fierce 15 Top Biotech Companies Jun-24-2008, 11:00AM EDT
-
Alnylam and Kyowa Hakko Form Alliance for the Development and Commercialization of ALN-RSV01 in Asia Jun-19-2008, 03:00AM EDT
News From Around the Web
News
-
Alnylam Grants Calando License to Further siRNA Cancer Therapeutic Program
(Genetic Engineering News)Jul 22 2008 -
Alnylam grants RNAi license to Calando Pharma
(Mass High Tech)Jul 21 2008 -
Movers roundup: Tuesday Morning, Teva Pharma
(Boston Globe)Jul 11 2008
Employees
Number of Employees: 129
Revenue per Employee: $324,967
Top Executives
Board of Directors
Dr. Paul R. Schimmel, Ph.D., Founder/Director
Dr.Victor J. Dzau, M.D., Director
Kevin P. Starr, Director
Dr. Edward M. Scolnick, M.D., Director
Dr.Phillip A. Sharp, Ph.D., Founder/Director
James L. Vincent, Director
Patricia L. Allen, CPA, Divisional Vice President/Treasurer/CFO
Dr. Vicki L. Sato, Director
John K. Clarke, Chairman of the Board/Director/Founder
Financials
Quarterly
Annual
| Income Statement | 05/2008 | 02/2008 | 11/2007 | 08/2007 |
|---|---|---|---|---|
| Sales | NA | NA | -1.05 Mil. | -937 K. |
| Gross Operating Profit | 22.19 Mil. | 18.23 Mil. | 17.36 Mil. | 10.07 Mil. |
| Operating Income before D & A (EBITDA) | -3.96 Mil. | -2.89 Mil. | -50.29 Mil. | -14.02 Mil. |
| Total Income Before Interest Expenses (EBIT) | -802 K. | 1.97 Mil. | -47.34 Mil. | -12.42 Mil. |
| Total Net Income | -1.24 Mil. | 1.66 Mil. | -52.79 Mil. | -12.69 Mil. |
| Basic EPS, Total | -0.03 | 0.04 | -1.35 | -0.34 |
| Diluted EPS, Total | -0.03 | 0.04 | -1.35 | -0.34 |
| BALANCE STATEMENT | 05/2008 | 02/2008 | 11/2007 | 08/2007 |
|---|---|---|---|---|
| Cash and Equivalents | 443.87 Mil. | 455.6 Mil. | 200.55 Mil. | 84.46 Mil. |
| Total Assets | NA | 463.56 Mil. | 477.63 Mil. | 201.96 Mil. |
| Total Liabilities | 26.09 Mil. | 289.12 Mil. | 87.46 Mil. | 27.11 Mil. |
| Total Capitalization | 204.77 Mil. | 199.17 Mil. | 196.88 Mil. | 184.18 Mil. |
| Cash Flow | 05/2008 | 02/2008 | 11/2007 | 08/2007 |
|---|---|---|---|---|
| Net Cash From Continuing Operations | NA | NA | 204.96 Mil. | -19.35 Mil. |
| Net Cash From Investing Activities | NA | NA | -189.74 Mil. | -23.85 Mil. |
| Net Cash From Financing Activities | NA | NA | 57.88 Mil. | -93 K. |
| Net Change in Cash & Cash Equivalents | NA | NA | 72.59 Mil. | -43.49 Mil. |
| Income Statement | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|
| Sales | NA | -3.82 Mil. | -3.12 Mil. | -2.44 Mil. |
| Gross Operating Profit | 50.9 Mil. | 30.74 Mil. | 8.84 Mil. | 6.72 Mil. |
| Operating Income before D & A (EBITDA) | -93.18 Mil. | -35.69 Mil. | -40.35 Mil. | -29.82 Mil. |
| Total Income Before Interest Expenses (EBIT) | -79.14 Mil. | -33.58 Mil. | -41.94 Mil. | -31.99 Mil. |
| Total Net Income | -85.47 Mil. | -34.61 Mil. | -42.91 Mil. | -32.65 Mil. |
| Basic EPS, Total | -2.21 | -1.09 | -1.96 | -2.98 |
| Diluted EPS, Total | -2.21 | -1.09 | -1.96 | -2.98 |
| BALANCE STATEMENT | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|
| Cash and Equivalents | 455.6 Mil. | 127.96 Mil. | 15.76 Mil. | 20.27 Mil. |
| Total Assets | 463.56 Mil. | 222.78 Mil. | 82.41 Mil. | 48.18 Mil. |
| Total Liabilities | 289.12 Mil. | 22.92 Mil. | 18.48 Mil. | 6.58 Mil. |
| Total Capitalization | 199.17 Mil. | 207.09 Mil. | 67.3 Mil. | 52.55 Mil. |
| Cash Flow | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|
| Net Cash From Continuing Operations | NA | -24.63 Mil. | -16.48 Mil. | -19.57 Mil. |
| Net Cash From Investing Activities | NA | -30.05 Mil. | -40.42 Mil. | -34.6 Mil. |
| Net Cash From Financing Activities | NA | 166.63 Mil. | 52.62 Mil. | 50.98 Mil. |
| Net Change in Cash & Cash Equivalents | NA | 112.2 Mil. | -4.52 Mil. | -2.92 Mil. |
Related Companies by Market Cap
Company Name
Price
Change
Market Cap
1.26 Bil.
1.35 Bil.
1.17 Bil.
1.14 Bil.
Company Profile Change Request
The data provided in our company profiles comes from third party information providers.- If you have a change request regarding a publicly traded company, click here
- If your request pertains to a private company, click here
Also in Portfolio.com
Most Emailed
Recently Commented
TOP 5
(Daily)
A smart take on the top stories shaping the business world.
Executives & Careers
(Tuesdays)
A weekly guide to the personalities and ideas that are transforming the business world.
Inside Portfolio.com
(Wednesdays)
Our roundup of the week's best from Portfolio.com.
Culture & Lifestyle
(Fridays)
A weekly guide to the best ways to spend your time - and money.
In This Issue
(Monthly)
Be the first to know when the latest issue of Condé Nast Portfolio magazine is online.


